Emergency Opioid Antagonists in Public K-12 Schools and Postsecondary Educational Institutions:
HB 355 would expand Florida law governing emergency opioid antagonists in schools by allowing public K-12 schools to purchase, use, and maintain a supply of FDA-approved emergency opioid antagonists that meet the bill’s definition, rather than limiting the statute to naloxone alone. The bill also revises the definition of “emergency opioid antagonist” in the postsecondary housing statute to mean naloxone hydrochloride or any similarly acting FDA-approved drug that blocks the effects of opioids when administered from outside the body.
In practical terms, the bill is aimed at improving preparedness for opioid overdoses in public schools, Florida College System institutions, and state university housing. It preserves the existing framework that allows schools to obtain these medications through wholesale distributors or manufacturers and to keep them in secure locations, and it continues to recognize civil liability immunity for school district employees who administer an approved antagonist in compliance with existing law.
The bill would amend s. 1002.20, F.S., and s. 1004.0971, F.S., broadening the types of emergency opioid antagonists that public schools and postsecondary institutions may stock and use. It would not create a new program, but would update existing school health and overdose-response statutes to cover additional FDA-approved opioid reversal medications beyond naloxone, while leaving the current immunity and storage provisions in place. The act would take effect July 1, 2025.
The available context suggests generally favorable policy support for the bill’s public-safety goal, since it was designed to expand access to overdose-reversal medication in educational settings. However, the bill ultimately died in the Senate Rules Committee, and the legislative record indicates that a companion measure, CS/CS/HB 1255, passed instead. That outcome suggests the underlying issue had support, but this particular bill did not advance to enactment.
The main point of contention appears to have been legislative vehicle and duplication rather than the substance of opioid-overdose preparedness itself. The bill’s narrower focus on school and campus opioid antagonists may have overlapped with the companion bill that ultimately passed, which likely reduced the need for HB 355 to move forward independently. No committee transcript or recorded vote information is available here to show direct opposition on policy grounds.